Emerging technologies for cancer detection and diagnosis are providing more and more advance warning of pathologies of clinical significance. Research devoted to cancers are revealing new ways of finding and treating these complex diseases. This volume reviews a broad array of new technologies for cancer detection and diagnosis. While there are several clinical books describing cancer diagnosis, and general molecular analytical technologies, these books are not focused on cancer detection and diagnosis. The aim of this book is to describe emerging cancer detection and diagnosis technologies.
Key Features
• Presents myriad new experimental cancer detection technologies
• Describes technology so the reader may conduct similar analyses
• Outlines clinical applications of technology for specific cancer and summarizes results
• Discusses pitfalls and limitations, future trends and potential technological developments
Miguel Ossandon has a dual background in clinical laboratory and computer science. He started working in cancer research at the Lombardi Cancer Center at Georgetown University where he also began his undergraduate training in computer science. He has been working for the National Cancer Institute since 2007. Miguel received his master’s degree at the George Washington University and PhD in computer science at the University of Maryland Baltimore County. As a program director in the Diagnostic Biomarkers and Technology Branch, he manages a grant portfolio related to computational modeling and machine learning approaches for cancer diagnosis, digital image processing/analysis, and microfluidic and circulating tumor cell technology.
Ben Prickril is a former US government official working at the US National Institutes of Health, National Cancer Institute. He has a background in medically related chemistry, microbiology, immunology, patenting and intellectual property, and global health. International research development includes experience in France, Turkey, Ukraine, Czech Republic and Burkina Faso. He received his PhD from the University of Georgia.
Avraham Rasooly is in the Division of Cancer Treatment and Diagnosis, National Cancer Institute. He has been responsible for developing research programs on new approaches for cancer therapy, including technologies for microbial-based cancer therapy. He received his PhD from Michigan State University.
Near-infrared macroscopic and mesoscopic fluorescence lifetime FRET imaging to measure intra-tumor heterogeneity of antibody-target engagement. Combined Reflectance Confocal Microscopy- Optical Coherence Tomography for Skin Cancer Detection and Therapy GuidanceIn Vivo Confocal Laser Endomicroscopy: An Imaging Biomarker for Risk Stratification of Precancerous Pancreatic Cystic Lesions. Portable confocal microscopy for aiding diagnosis and treatment of skin cancer
Quantitative fluorescence imaging, light-triggering and monitoring of chemodrug release from liposomes in vivo by a mesoscopic-scale theranostic endoscope.Fluorescence Imitating Brightfield Imaging (FIBI): A simple slide-free microscopy approach.Fluorescently-labeled tyrosine kinase inhibitors for intracellular protein target imaging.Real-time Cancer Metabolism Detection Using a Nanocoil Integrated Hyperpolarized Micromagnetic Resonance Spectrometer. Detection of TMEM doorways and their activity required for metastasis. Reading the Reader: Utilizing Eye-Movements and Machine Learning to Enhance Accuracy. During Diagnostic Visual Search.Optical Imaging Technology for In Vivo Tumor Detection.Adapting Image Foundational Model to Identify Tumor Budding from H&E Images in Colorectal Cancer Diagnostics.Quantitative Phase Imaging for Assessing Tumor Cell Adaptability.An Exo-PROS Biosensor Simultaneously Detects Tumor-Derived Exosomal Protein-MicroRNA Pairs for Lung and Breast Cancer Diagnosis.Epigenetic Tools for Guiding Low Dose Computerized Tomography (LDCT) Screening Decision Making.Multi-View Models for Colorectal Polyps Detection in CT Colonography.Hybrid Multi-dimensional MRI of Prostate Cancer.Detection and Characterization of Brain Metastases Using Quantitative Chemical Exchange Saturation Transfer MRFingerprinting (CEST-MRF).Narrow-Beam CT: A Solution to the Limitations in Breast Cancer Screening.Broadband Coherent Anti-Stokes Raman Scattering Microscopy for Metabolic and Phenotypic Imaging in Cancer.
Spatial multiplexed immunofluorescence imaging in exploring tumor immune microenvironment of melanoma.
Spectroscopic Optical Coherence Tomography for in situ analysis of colonic epithelium.Analysis of Circulating Tumor DNA (ctDNA) by Digital Droplet PCR (ddPCR).Non-invasively monitoring the delivery of DNA alkylating agents and cellular responses to these agents using chemical exchange saturation transfer magnetic resonance imaging.Clonal Analysis of Cancer by Mitochondrial DNA Barcoding.Implementing Clinical Risk Assessment for Genetic Susceptibility to Cancer: Challenges and Successes in a Statewide Initiative.Assessing tumor tissue for the alternative lengthening of telomeres (ALT) phenotype.Click Chemistry-Mediated Enrichment of Tumor-Derived Extracellular Vesicles for RNA-Based Digital Scoring.Identifying Methods to Deliver Mutant p53-basedDiagnostics and Therapeutics to Target the Previously Undruggable.DNA methylation biomarkers for preoperative diagnostic of thyroid nodules.
Utilizing RADAR for the Integration of Genomic Data and Immunotherapy Targets in Precision Oncology for Multiple Myeloma.Nanopore Whole Transcriptome Sequencing Offers the Potential for Accessible Classification of Pediatric Cancers.Quantitative detection of cancer nucleic acid biomarkers with a selective solid-state nanopore assay.Isolation and characterization of cell-free RNA from liquid biopsy taken from cancer patients.The Use of Dielectrophoresis to Recover Cancer. Derived Nanoparticles Straight from Undiluted Human Plasma for Cancer. Detection Applications.Conditional Reprogramming: A. Living Biomarker and Phenotypic Screening Drug Platform for Urological Cancer.Proteolytic Activity Signatures As Candidate. Biomarkers for Thyroid Cancer. Carbohydrate microarrays identify the stage-specific embryonic antigen (SSEA)-0 as a novel oncofetal cancer marker.Collective Attributes of Extracellular Vesicles as Biomarkers for Cancer Detection .Using a gamified mobile app approach to train tobacco control program implementers in schools in India. Parallel Reaction Monitoring (PRM) Quantitative. Analysis of Glycopeptide Biomarkers from Patient Serum.Point-of-care technologies for molecular subtyping of breast cancer in low- and middle-income countries.Development Of LLM For Prostate Cancer - The Need for Domain-Tailored Training.Biosample and Method Selection for Marker Studies.Subharmonic-aided pressure estimation for evaluating cancer.
Development and Implementation of a Method for Registering Prostate-specific Antigen (PSA) Biosensor-based Assay Results in a Personalized QR Code. Deep Learning-based Colon Segmentation for Accurate Colorectal Polyps Detection. Emerging Blood-based Tests for Colorectal Cancer Screening: Advances, Challenges and Future Directions. Microfluidic Isolation and Molecular Characterization of Circulating Tumor Cells in Prostate Cancer. Chemical Imaging for Next-generation Histopathology. GALAD Score and Extracellular Vesicle-based Assays for Early Detection of Hepatocellular Carcinoma. Using epidemiologic research methods to adapt a human papillomavirus assay for cervical cancer screening in low and middle income countries. Organoid Models for Early Detection and Diagnosis of Colorectal Cancer. Experimental Methods for Establishing and Maintaining Canine Bladder Cancer Organoids. Top-down Proteomics of Cancer Cells by Advanced Capillary Electrophoresis-Mass Spectrometry.
Height:
Width:
Spine:
Weight:0.00